Agency Agreement Conditions for Medical Device Registration in Ethiopia

1. Key takeaways

Foreign manufacturers who want to register and sell medical devices in Ethiopia must first sign an Agency Agreement with a local agent. Section 9.2.3 of EFDA-GDL-046 (Fourth Edition) lists eight conditions (items a–h), while Section 9.2.2 establishes the exclusivity rule that the same product must not be authorized to more than one registration holder or local agent at the same time. The agreement must be signed and sealed by both parties, state the agent’s ranking position, allocate shared responsibility for recalls and vigilance, and include a commitment to submit safety and performance evidence for Class III and above devices and Class C and above IVDs within one year of market placement; the agreement remains valid for at least one year from the date of submission; and the agent responsible for importing must hold a license issued by the Ministry of Trade and a Certificate of Competence (CoC) issued by EFDA at the time of import. EFDA reviews the agreement itself as a regulatory submission, so any missing condition can sink the application before the technical file is examined.

2. Legal basis

3. Expert insights

Insight 1: The sole-agent rule and the multiple-agent possibility do not contradict each other; the constraint applies to the same product.

Section 9.2.2 is explicit that the authorization holder or manufacturer must not, at the same time, authorize more than one registration holder or local agent for the same product. Section 9.2.3(c), by contrast, allows different products of the same authorization holder to be registered or imported by different agents, provided the agreement states the agent’s ranking position (first, second or third agent). Taken together, these provisions create a practical iron rule for portfolio planning: one product, one agent; multiple products may go through multiple agents, but every agreement must be sequenced. A manufacturer with a broad catalog can therefore structure a multi-agent network, provided every agreement carries its position marker and no device model appears under two agents at once.

Insight 2: The responsibility clauses are mandatory content, not negotiating room in a commercial contract.

Item (d) requires that where fraud or an unacceptable unexpected adverse event occurs under normal conditions of use, both parties are jointly responsible for recalling the product from the market and for providing evidence. Item (f) requires the parties to jointly bear responsibility for device vigilance and post-market reporting. These two provisions push the local agent out of the role of a nominal representative and into the position of a co-bearer of compliance responsibility. Foreign manufacturers should not assume they can contractually push all post-market obligations onto themselves; a one-sided draft may be rejected as non-conforming.

Insight 3: The one-year post-market evidence commitment for high-risk devices is written into the agreement itself.

Item (e) requires the agreement to provide that, for all Class III and above devices and Class C and above IVDs, the authorization holder and the local representative must submit evidence of device safety and performance to EFDA within one year of placement on the Ethiopian market. This effectively moves post-market evidence collection forward in time, converting it into a registration-stage commitment. An application whose agreement omits this clause is considered not to satisfy the conditions, so the defect surfaces at intake and adds a full resubmission cycle.

Insight 4: Form and logistics trip up applicants more often than substance.

The instructions of Annex IV further specify: the submission must include proof of payment of the 50 USD agency agreement fee; the original agreement must be mailed to the EFDA archive room through DHL in unopened, properly sealed packaging; after signing, both a scanned PDF soft copy and the paper copy must be submitted, together with the payment receipt and a stamped fee instruction (stored on CD or USB flash drive and returned to the applicant after upload to the system); a valid scanned PDF of the CoC must be provided; and the body of the agreement must not exceed 5 pages and must not contain information that is redundant from a regulatory perspective. Every one of these formalities is independently checkable, and a failure on any single one can bounce the whole package.

Insight 5: Three-party chains have a defined order of documentation.

Where the entity applying for registration is not the actual manufacturer, a three-party agreement between the actual manufacturer, the supplier and the local agent must be submitted, along with a two-party agreement between the manufacturer and the supplier. Where a manufacturer produces at two or more sites, agreements defining the division of responsibility between the sites must be provided, and the agency agreement must be anchored to the site that keeps the dossier and acts as the registration applicant. This prevents ambiguity over which legal entity carries the registration obligations when production or supply is distributed across jurisdictions.

4. Practical recommendations

1. Screen for conflicts with a product-agent matrix before signing: confirm that the same registration unit is not simultaneously authorized to two local agents, then execute the agreement.
2. Draft items (d), (e) and (f) as executable clauses: specify mechanisms, deadlines and responsible persons for recall cooperation, vigilance reporting channels and post-market evidence submission, rather than simply writing that both parties are jointly responsible.
3. Leave buffer in the validity period: the agreement must be valid for at least one year from submission; set the term at the expected review cycle plus 12 months so the agreement cannot lapse mid-review.
4. Have the importing agent secure the CoC before any import starts: item 9.2.3(h) uses the time of import as the judging point; clearing customs without a CoC creates a compliance gap that cannot be cured retroactively.
5. Control the length of the agreement: the body is limited to 5 pages; move commercial side terms into a separate document that is not submitted to the authority.
6. Follow the Annex IV physical logistics exactly: the DHL unopened original, the PDF soft copy, the paper copy and the payment receipt are all required; none of the four can be omitted or substituted.

5. Verification checklist

• □ Confirmed that the same product is not authorized to two local agents at the same time
• □ The agreement contains all eight conditions (a)–(h)
• □ Both parties have signed and applied their seals
• □ The agent’s ranking position (first / second / third agent) is stated
• □ Shared responsibility clauses for recalls and vigilance are included
• □ The commitment to submit evidence within one year of market placement for high-risk devices is written in
• □ The agreement is valid for at least one year from the date of submission
• □ The importing agent holds the Ministry of Trade license and a valid CoC
• □ The proof of payment of the 50 USD agency agreement fee is attached
• □ The body of the agreement does not exceed 5 pages, and mailing and uploading per Annex IV are complete

Regulatory information verified as of October 29, 2026. The eight conditions and submission-form requirements listed in this article are governed by the current text of Sections 9.2.2 and 9.2.3 and Annex IV of the fourth edition of EFDA-GDL-046; when the guideline is revised or the templates are updated, the provisions must be re-checked.

Local resource in Ethiopia: GRZAN supports manufacturers from the Chinese mainland and overseas in engaging with the Ethiopian Food and Drug Authority (EFDA) on market authorization (MA), Certificate of Competence (CoC) and import permit applications, including local agent structuring and agency agreement review, SRA reliance pathway justification, UMDN coding and classification determination, technical documentation preparation, and the establishment of vigilance and post-market surveillance systems. Service capabilities cover product attribute determination and risk classification (non-IVD Class I–IV / IVD Class A–D), market authorization applications and re-registration, applicability assessment for the low-risk notification procedure, Essential Principles conformity reasoning, label and instruction-for-use localization in English, and vigilance reporting with field safety corrective action support. Contact: hito.lin@grzan.cn; website www.grzan.cn. For agency agreement drafting, review and local authorized representative support in the Ethiopian market, GRZAN can also be reached at info@grzanglobal.com.